Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
22 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
2 Nov 23
8-K
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
12 Oct 23
8-K
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
31 May 23
8-K
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
25 May 23
8-K
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4 May 23
8-K
Regulation FD Disclosure
18 Apr 23
8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
23 Feb 23
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
424B7
Prospectus with selling stockholder info
10 Jan 24
D
$30.00 mm in equity, sold $30.00 mm, 1 investor
10 Jan 24
424B7
Prospectus with selling stockholder info
16 Nov 23
S-8
Registration of securities for employees
23 Feb 23
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
12 Sep 22
424B7
Prospectus with selling stockholder info
1 Sep 22
S-8
Registration of securities for employees
24 Feb 22
424B5
Prospectus supplement for primary offering
13 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
PRE 14A
Preliminary proxy
1 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Apr 21
DEF 14A
Definitive proxy
7 Apr 21
Other
EFFECT
Notice of effectiveness
7 May 21
CORRESP
Correspondence with SEC
4 May 21
UPLOAD
Letter from SEC
3 May 21
EFFECT
Notice of effectiveness
16 Jul 20
CERT
Certification of approval for exchange listing
15 Jul 20
CORRESP
Correspondence with SEC
14 Jul 20
UPLOAD
Letter from SEC
14 Jul 20
CORRESP
Correspondence with SEC
13 Jul 20
CORRESP
Correspondence with SEC
13 Jul 20
CORRESP
Correspondence with SEC
9 Jul 20
Ownership
SC 13G/A
Casdin Capital, LLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Peter Rahmer
31 Jan 24
4
Thomas Catinazzo
31 Jan 24
4
Donald A Bergstrom
31 Jan 24
4
Brian Adams
31 Jan 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Peter Rahmer
18 Jan 24